SangStat To Introduce SangCya At 20%-28% Discount To Novartis Neoral
SangStat SangCya will be introduced at a 20%-28% discount to Novartis' cyclosporine product Neoral. The company estimated that the difference in pricing will lead to an annual savings of approximately $1,200 per patient receiving the anti-rejection therapy following organ transplantation.
You may also be interested in...
Novartis will offer blood level monitoring for transplant patients switching from Abbott's Gengraf to other cyclosporine products if the company's motion to have Gengraf removed from the market is granted
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011